Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-06-20Clinical Trial Update: Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place. [Phase 1]
Phase 1 healthy volunteer study evaluating three modified-release formulations of firategrast to assess how quickly the drug is absorbed fro…
-
CLINICAL_TRIALS trial_result · 2017-06-09Clinical Trial Update: Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants [Phase 4]
A Phase 4 trial comparing natalizumab and fingolimod in relapsing-remitting multiple sclerosis was terminated, with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-06-07Clinical Trial Update: A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 1]
A first-in-human Phase 1 study of GSK2618960 in healthy volunteers and relapsing-remitting multiple sclerosis patients has been terminated.
-
CLINICAL_TRIALS trial_result · 2017-05-30Clinical Trial Update: Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis [Phase 2]
Phase 2 pilot trial evaluating raltegravir (Isentress) in relapsing-remitting multiple sclerosis. The study has completed and results were p…
-
CLINICAL_TRIALS research · 2017-05-15Clinical Trial Update: An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab [Phase 3]
A clinical trial update describes an extension protocol for patients with relapsing-remitting multiple sclerosis who previously participated…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-05-11Clinical Trial Update: A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 2]
Phase 2 study evaluating the efficacy and safety of ocrelizumab in relapsing-remitting multiple sclerosis; the trial is completed with resul…
-
CLINICAL_TRIALS trial_result · 2017-04-28Clinical Trial Update: Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS [Phase 2]
This Phase 2 study reports results on how BG00012 (dimethyl fumarate) affects MRI lesions and pharmacokinetics in pediatric subjects with re…
-
CLINICAL_TRIALS trial_result · 2017-04-27Clinical Trial Update: Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 [Phase 3]
A Phase 3 clinical trial assessing cognitive outcomes in relapsing-remitting multiple sclerosis patients treated with BG00012 (dimethyl fuma…
-
CLINICAL_TRIALS trial_result · 2017-04-18Clinical Trial Update: Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany [Phase 4]
Phase 4 clinical trial update reporting results on the gastrointestinal tolerability of dimethyl fumarate in participants with Relapsing-Rem…
-
CLINICAL_TRIALS trial_result · 2017-04-04Clinical Trial Update: High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study [Phase 2]
Phase 2 trial update for high-dose immunosuppression and autologous transplantation in relapsing-remitting multiple sclerosis has completed …
-
CLINICAL_TRIALS trial_result · 2017-03-27Clinical Trial Update: Safety of RG2077 in Patients With Multiple Sclerosis [Phase 1]
Phase 1 safety update reporting on RG2077 in patients with multiple sclerosis, including relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS research · 2017-03-23Clinical Trial Update: Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
An observational study completed to characterize real-world clinical outcomes in relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis [Phase 3]
Phase 3 trial evaluating oral prolonged-release dalfampridine (BIIB041) for safety and efficacy in Japanese participants with multiple scler…
-
CLINICAL_TRIALS trial_result · 2017-03-14Clinical Trial Update: An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis [Phase 3]
Open-label Phase 3 study evaluating immunogenicity and pharmacokinetics of Daclizumab High Yield Process Prefilled Syringe in Relapsing-Remi…
-
CLINICAL_TRIALS trial_result · 2017-03-07Clinical Trial Update: Rebif® Rebidose® Versus Rebiject II® Ease-of-Use [Phase 4]
Phase 4 trial comparing Rebif Rebidose to Rebiject II for ease of use in patients with relapsing-remitting multiple sclerosis; results were …
-
CLINICAL_TRIALS trial_result · 2017-02-27Clinical Trial Update: Minocycline in Clinically Isolated Syndromes (CIS) [Phase 3]
Phase 3 trial of minocycline in Clinically Isolated Syndrome and early relapse of multiple sclerosis has completed; results are not detailed…
-
CLINICAL_TRIALS research · 2017-02-24Clinical Trial Update: Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). [Phase 1]
A Phase 1 study evaluating safety, biodistribution, radiation dosimetry, and imaging protocol optimization of GEH120714 (18F) injection in h…
-
CLINICAL_TRIALS trial_result · 2017-01-30Clinical Trial Update: Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 3]
Phase 3 long-term safety and efficacy study of teriflunomide at 7 mg and 14 mg in relapsing-remitting multiple sclerosis completed with resu…
-
CLINICAL_TRIALS trial_result · 2017-01-27Clinical Trial Update: Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen
This completed clinical trial evaluated tolerability and quality of life in people who switched to the Avonex Pen (interferon beta-1a) for r…
-
CLINICAL_TRIALS trial_result · 2017-01-11Clinical Trial Update: Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis [Phase 1, Phase 2]
An update on a dose-escalation Phase 1/2 trial of Opexa's autologous T cell vaccine for relapsing-remitting and secondary progressive multip…
-
CLINICAL_TRIALS trial_result · 2017-01-09Clinical Trial Update: Safety Study of BIIB033 in Subjects With Multiple Sclerosis [Phase 1]
A Phase 1 safety study of Opicinumab (BIIB033) in subjects with Relapsing-Remitting Multiple Sclerosis and Multiple Sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2017-01-06Clinical Trial Update: Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation [Phase 4]
Phase 4 pilot study investigating strategies to mitigate GI symptoms associated with dimethyl fumarate in Relapsing-remitting multiple scler…
-
CLINICAL_TRIALS trial_result · 2016-12-28Clinical Trial Update: Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis [Phase 4]
Phase 4 trial evaluating whether aspirin mitigates flushing in patients with relapsing-remitting multiple sclerosis treated with dimethyl fu…
-
CLINICAL_TRIALS trial_result · 2016-12-21Clinical Trial Update: Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839 [Phase 2]
Phase 2 trial update for Vatelizumab in relapsing-remitting multiple sclerosis; efficacy and safety data in patients who completed study DRI…
-
CLINICAL_TRIALS trial_result · 2016-12-21Clinical Trial Update: Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Vatelizumab in relapsing-remitting multiple sclerosis was terminated.